Serum amylase elevation is associated with adverse clinical outcomes in patients with coronavirus disease 2019

Li, Ganxun; Liu, Tongtong; Jin, Guan-Nan; Li, Tianhong; Liang, Jintai; Chen, Qian; Chen, Lin; Wang, Wei; Wang, Yuwei; Song, Jia; Liang, Huifang; Zhang, Chuanhan; Zhu, Peng; Zhang, Wanguang; Ding, Zhao; Chen, Xiaoping; Zhang, Bixiang; Covid, Tongji multidisciplinary Team for Treating

doi:10.18632/aging.203653

Cited by 8 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the heterogeneity was significant, we performed a sensitivity analysis to explore the impact of each study. The result showed that two studies ( 13 , 23 ) affected the pooled OR (odds ratio) of mortality ( Supplementary Figure 2 ). After removing any one of the two studies, the I 2 did not decrease significantly (78.6–87.7%).…”

Section: Resultsmentioning

confidence: 99%

“…Table 1 summarized the characteristic of the included studies. Thirteen studies were from the USA ( n = 5), China ( n = 3), Italy ( n = 2), Turkey ( n = 2), and Germany ( n = 1), of which, 12 were retrospective, one ( 24 ) was prospective, and five studies ( 14 , 16 , 23 , 25 , 29 ) were multicenter. The sample size ranged from 38–17225, and the proportion of male participants varied from 44.6–78.9%.…”

Section: Resultsmentioning

confidence: 99%

“…Each study had a clear definition of PE elevation, however, it lacked a unified standard and there was an obvious heterogeneity in the definition of upper normal limit (ULN). Ten studies ( 12 – 14 , 16 , 21 – 23 , 26 , 27 , 29 ) defined PE elevation as > ULN, and three studies ( 24 , 25 , 28 ) defined PE elevation as > 3 × ULN. The results of quality assessment were shown in Supplementary Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Ten studies ( 13 , 14 , 16 , 21 – 23 , 25 – 27 , 29 ) reported the mortality associated with elevated PE. A total of 2,4207 participants including 3,142 participants in the elevated PE group, of which 760 participants died, and 2,1065 participants in the normal PE group, of which 2,033 participants died were included in the analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Subsequently, we performed a subgroup analysis based on the definition of PE elevation and data sources. Ten studies were divided into the 1–3 ULN group ( 13 , 14 , 21 , 23 , 26 , 29 ) and the >3 × ULN group ( 13 , 14 , 21 , 23 , 25 , 26 , 29 ) (six studies ( 13 , 14 , 21 , 23 , 26 , 29 ) reported the two conditions). The 1–3 ULN group involved 1,330 participants, of which 424 died, and the >3 × ULN group involved 1,754 participants, of which 308 died.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Prevalence and Outcomes of Pancreatic Enzymes Elevation in Patients With COVID-19: A Meta-Analysis and Systematic Review

Zhou

Yang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

Background:Although coronavirus disease 2019 (COVID-19) is considered to be a disease that mainly involves the respiratory system, an increasing number of studies have reported that COVID-19 patients had pancreatic enzymes (PE) elevation and even pancreatic injury. The study aims to determine the prevalence of PE elevation, and the relationship between elevated PE and prognosis in COVID-19 patients.MethodsA comprehensive literature search was conducted according to the PRISMA guideline in PubMed, Embase, Scopus, Web of Science, and Google Scholar for studies reporting PE elevation in patients with COVID-19 from 1st January 2020 to 24th November 2021.ResultsA total of 13 studies (24,353 participants) were included in our review. The pooled prevalence of PE elevation in COVID-19 patients was 24% (18%–31%), the pooled odds ratio (OR) of mortality was 2.5 (1.7–3.6), the pooled OR of ICU admission was 4.4 (2.8–6.8), and the pooled OR of kidney injury, respiratory failure and liver injury were 3.5 (1.6–7.4), 2.0 (0.5–8.7), and 2.3 (1.4–3.9) respectively. In addition, the subgroup analysis revealed that although PE elevated to > 3 × upper normal limit (ULN) was significantly related to the mortality (OR = 4.4, 2.1–9.4), it seemed that mild elevation of PE to 1–3 ULN also had a considerable risk of mortality (OR = 2.3, 1.5–3.5).ConclusionsPE elevation was a common phenomenon in patients with COVID-19, and was associated with poor clinical outcomes. However, due to the limited numbers of included studies, the result of our study still needed to be validated.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=295630, identifier: CRD42021295630.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence and Outcomes of Pancreatic Enzymes Elevation in Patients With COVID-19: A Meta-Analysis and Systematic Review

Zhou

Yang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

Eliminating COVID‐19 as the immediate culprit for igniting pancreatitis

Ge,

Luo,

Liu

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The impact of severe acute respiratory syndrome coronavirus 2 infection on the potential development of pancreatitis is a subject of ongoing debate within academic discourse. Establishing a causal link between COVID‐19 and pancreatitis may not be fully supported by relying only on retrospective studies or case reports. This study examined the relationship between COVID‐19 phenotypes and pancreatitis by Mendelian randomization (MR) method. The identification of instrumental variables (single nucleotide polymorphisms) that exhibit a robust association with the COVID‐19 phenotypes was accomplished through a meticulous process of rigorous screening procedures. We included acute pancreatitis and chronic pancreatitis (CP) as the outcomes in the MR analysis, even though no definitive studies exist between COVID‐19 and CP. A direct causal relationship between genetically predicted COVID‐19 phenotypes and pancreatitis risk cannot be established. There is an ongoing debate over the designation of COVID‐19 as a definitive cause of pancreatitis.

show abstract

The Pancreas in Coronavirus Disease 2019 Infection

Sá

Rocha

2023

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

Serum amylase elevation is associated with adverse clinical outcomes in patients with coronavirus disease 2019

Cited by 8 publications

References 39 publications

Prevalence and Outcomes of Pancreatic Enzymes Elevation in Patients With COVID-19: A Meta-Analysis and Systematic Review

Prevalence and Outcomes of Pancreatic Enzymes Elevation in Patients With COVID-19: A Meta-Analysis and Systematic Review

Eliminating COVID‐19 as the immediate culprit for igniting pancreatitis

The Pancreas in Coronavirus Disease 2019 Infection

Contact Info

Product

Resources

About